The pH Dependence of Niclosamide Solubility, Dissolution, and Morphology: Motivation for Potentially Universal Mucin-Penetrating Nasal and Throat Sprays for COVID19, its Variants and other Viral Infections

{ 'indexed': {'date-parts': [[2024, 3, 25]], 'date-time': '2024-03-25T13:14:37Z', 'timestamp': 1711372477301}, 'reference-count': 73, 'publisher': 'Springer Science and Business Media LLC', 'issue': '1', 'license': [ { 'start': { 'date-parts': [[2021, 12, 28]], 'date-time': '2021-12-28T00:00:00Z', 'timestamp': 1640649600000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.springer.com/tdm'}, { 'start': { 'date-parts': [[2021, 12, 28]], 'date-time': '2021-12-28T00:00:00Z', 'timestamp': 1640649600000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'https://www.springer.com/tdm'}], 'content-domain': {'domain': ['link.springer.com'], 'crossmark-restriction': False}, 'published-print': {'date-parts': [[2022, 1]]}, 'DOI': '10.1007/s11095-021-03112-x', 'type': 'journal-article', 'created': { 'date-parts': [[2021, 12, 28]], 'date-time': '2021-12-28T16:02:27Z', 'timestamp': 1640707347000}, 'page': '115-141', 'update-policy': 'http://dx.doi.org/10.1007/springer_crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 11, 'title': 'The pH Dependence of Niclosamide Solubility, Dissolution, and Morphology: Motivation for ' 'Potentially Universal Mucin-Penetrating Nasal and Throat Sprays for COVID19, its Variants and ' 'other Viral Infections', 'prefix': '10.1007', 'volume': '39', 'author': [ { 'ORCID': 'http://orcid.org/0000-0002-0082-9148', 'authenticated-orcid': False, 'given': 'David', 'family': 'Needham', 'sequence': 'first', 'affiliation': []}], 'member': '297', 'published-online': {'date-parts': [[2021, 12, 28]]}, 'reference': [ { 'key': '3112_CR1', 'unstructured': 'CDC. SARS-CoV-2 Variant Classifications and Definitions ' 'https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html ' '2021. Accessed on 2021–11–21.'}, { 'issue': '2', 'key': '3112_CR2', 'doi-asserted-by': 'publisher', 'first-page': '417', 'DOI': '10.1016/j.ijpharm.2003.09.035', 'volume': '269', 'author': 'EC van Tonder', 'year': '2004', 'unstructured': 'van Tonder EC, Maleka TSP, Liebenberg W, Song M, Wurster DE, de Villiers ' 'MM. Preparation and physicochemical properties of niclosamide anhydrate ' 'and two monohydrates. Int J Pharm. 2004;269(2):417–32.', 'journal-title': 'Int J Pharm'}, { 'issue': '2', 'key': '3112_CR3', 'doi-asserted-by': 'publisher', 'first-page': 'e0246803-e', 'DOI': '10.1371/journal.pone.0246803', 'volume': '16', 'author': 'AD Brunaugh', 'year': '2021', 'unstructured': 'Brunaugh AD, Seo H, Warnken Z, Ding L, Seo SH, Smyth HDC. Development ' 'and evaluation of inhalable composite niclosamide-lysozyme particles: A ' 'broad-spectrum, patient-adaptable treatment for coronavirus infections ' 'and sequalae. PloS One. 2021;16(2):e0246803-e.', 'journal-title': 'PloS One.'}, { 'issue': '7861', 'key': '3112_CR4', 'doi-asserted-by': 'publisher', 'first-page': '88', 'DOI': '10.1038/s41586-021-03491-6', 'volume': '594', 'author': 'L Braga', 'year': '2021', 'unstructured': 'Braga L, Ali H, Secco I, Chiavacci E, Neves G, Goldhill D, et al. Drugs ' 'that inhibit TMEM16 proteins block SARS-CoV-2 spike-induced syncytia. ' 'Nature. 2021;594(7861):88–93.', 'journal-title': 'Nature'}, { 'key': '3112_CR5', 'doi-asserted-by': 'crossref', 'unstructured': 'Cabrita I, Benedetto R, Schreiber R, Kunzelmann K. Niclosamide ' 'repurposed for the treatment of inflammatory airway disease. JCI ' 'Insight. 2019;4(15).', 'DOI': '10.1172/jci.insight.128414'}, { 'issue': '9', 'key': '3112_CR6', 'doi-asserted-by': 'publisher', 'first-page': 'e0184324-e', 'DOI': '10.1371/journal.pone.0184324', 'volume': '12', 'author': 'B Cheng', 'year': '2017', 'unstructured': 'Cheng B, Morales LD, Zhang Y, Mito S, Tsin A. Niclosamide induces ' 'protein ubiquitination and inhibits multiple pro-survival signaling ' 'pathways in the human glioblastoma U-87 MG cell line. PloS One. ' '2017;12(9):e0184324-e.', 'journal-title': 'PloS One.'}, { 'issue': '2', 'key': '3112_CR7', 'doi-asserted-by': 'publisher', 'first-page': '996', 'DOI': '10.1128/AAC.01952-12', 'volume': '57', 'author': 'F Imperi', 'year': '2013', 'unstructured': 'Imperi F, Massai F, Ramachandran Pillai C, Longo F, Zennaro E, Rampioni ' 'G, et al. New life for an old drug: the anthelmintic drug niclosamide ' 'inhibits Pseudomonas aeruginosa quorum sensing. Antimicrob Agents ' 'Chemother. 2013;57(2):996.', 'journal-title': 'Antimicrob Agents Chemother'}, { 'key': '3112_CR8', 'doi-asserted-by': 'crossref', 'unstructured': 'Jeon S, Ko M, Lee J, Choi I, Byun SY, Park S et al. Identification of ' 'antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs. ' 'bioRxiv. 2020:2020.03.20.999730.', 'DOI': '10.1101/2020.03.20.999730'}, { 'issue': '10', 'key': '3112_CR9', 'doi-asserted-by': 'publisher', 'first-page': 'e1002976', 'DOI': '10.1371/journal.ppat.1002976', 'volume': '8', 'author': 'A Jurgeit', 'year': '2012', 'unstructured': 'Jurgeit A, McDowell R, Moese S, Meldrum E, Schwendener R, Greber UF. ' 'Niclosamide Is a Proton Carrier and Targets Acidic Endosomes with Broad ' 'Antiviral Effects. PLOS Pathogens. 2012;8(10):e1002976.', 'journal-title': 'PLOS Pathogens.'}, { 'issue': '11', 'key': '3112_CR10', 'doi-asserted-by': 'publisher', 'first-page': '1088', 'DOI': '10.1002/cmdc.201800100', 'volume': '13', 'author': 'H Kadri', 'year': '2018', 'unstructured': 'Kadri H, Lambourne OA, Mehellou Y. Niclosamide, a Drug with Many ' '(Re)purposes. ChemMedChem. 2018;13(11):1088–91.', 'journal-title': 'ChemMedChem'}, { 'key': '3112_CR11', 'doi-asserted-by': 'publisher', 'first-page': 'e39', 'DOI': '10.1038/bcj.2011.38', 'volume': '1', 'author': 'FL Khanim', 'year': '2011', 'unstructured': 'Khanim FL, Merrick BAME, Giles HV, Jankute M, Jackson JB, Giles LJ, et ' 'al. Redeployment-based drug screening identifies the anti-helminthic ' 'niclosamide as anti-myeloma therapy that also reduces free light chain ' 'production. Blood Cancer J. 2011;1:e39.', 'journal-title': 'Blood Cancer J'}, { 'issue': '12', 'key': '3112_CR12', 'doi-asserted-by': 'publisher', 'first-page': '3198', 'DOI': '10.1158/1078-0432.CCR-13-3296', 'volume': '20', 'author': 'C Liu', 'year': '2014', 'unstructured': 'Liu C, Lou W, Zhu Y, Nadiminty N, Schwartz CT, Evans CP, et al. ' 'Niclosamide inhibits androgen receptor variants expression and overcomes ' 'enzalutamide resistance in castration-resistant prostate cancer. Clin ' 'Cancer Res. 2014;20(12):3198–210.', 'journal-title': 'Clin Cancer Res'}, { 'key': '3112_CR13', 'doi-asserted-by': 'publisher', 'first-page': '60', 'DOI': '10.1016/j.reprotox.2016.11.005', 'volume': '70', 'author': 'CW McCollum', 'year': '2017', 'unstructured': 'McCollum CW, Conde-Vancells J, Hans C, Vazquez-Chantada M, Kleinstreuer ' 'N, Tal T, et al. Identification of vascular disruptor compounds by ' 'analysis in zebrafish embryos and mouse embryonic endothelial cells. ' 'Reprod Toxicol. 2017;70:60–9.', 'journal-title': 'Reprod Toxicol'}, { 'key': '3112_CR14', 'doi-asserted-by': 'crossref', 'unstructured': 'Miner K, Labitzke K, Liu B, Wang P, Henckels K, Gaida K, et al. Drug ' 'Repurposing: The Anthelmintics Niclosamide and Nitazoxanide Are Potent ' 'TMEM16A Antagonists That Fully Bronchodilate Airways. Front Pharmacol. ' '2019;10(51).', 'DOI': '10.3389/fphar.2019.00051'}, { 'issue': '19 Supplement', 'key': '3112_CR15', 'doi-asserted-by': 'publisher', 'first-page': '5491', 'DOI': '10.1158/1538-7445.AM2014-5491', 'volume': '74', 'author': 'RA Mook', 'year': '2014', 'unstructured': 'Mook RA, Zhao S, Chen W. Abstract 5491: Interrogating the mechanism of ' 'Wnt pathway inhibition by niclosamide. Can Res. 2014;74(19 ' 'Supplement):5491.', 'journal-title': 'Can Res'}, { 'key': '3112_CR16', 'doi-asserted-by': 'crossref', 'unstructured': 'Mostafa A, Kandeil A, Elshaier AMMY, Kutkat O, Moatasim Y, Rashad AA, et ' 'al. FDA-Approved Drugs with Potent In Vitro Antiviral Activity against ' 'Severe Acute Respiratory Syndrome Coronavirus 2. Pharmaceuticals. ' '2020;13(12).', 'DOI': '10.3390/ph13120443'}, { 'key': '3112_CR17', 'doi-asserted-by': 'crossref', 'unstructured': 'Prabhakara C, Godbole R, Sil P, Jahnavi S, van Zanten TS, Sheth D, et ' 'al. Niclosamide inhibits SARS-CoV2 entry by blocking internalization ' 'through pH-dependent CLIC/GEEC endocytic pathway. bioRxiv. ' '2020:2020.12.16.422529.', 'DOI': '10.1101/2020.12.16.422529'}, { 'issue': '6', 'key': '3112_CR18', 'doi-asserted-by': 'publisher', 'first-page': 'e0198389', 'DOI': '10.1371/journal.pone.0198389', 'volume': '13', 'author': 'MT Schweizer', 'year': '2018', 'unstructured': 'Schweizer MT, Haugk K, McKiernan JS, Gulati R, Cheng HH, Maes JL, et al. ' 'A phase I study of niclosamide in combination with enzalutamide in men ' 'with castration-resistant prostate cancer. PLOS ONE. ' '2018;13(6):e0198389.', 'journal-title': 'PLOS ONE.'}, { 'issue': '5', 'key': '3112_CR19', 'doi-asserted-by': 'publisher', 'first-page': '909', 'DOI': '10.1021/acsinfecdis.0c00052', 'volume': '6', 'author': 'J Xu', 'year': '2020', 'unstructured': 'Xu J, Shi P-Y, Li H, Zhou J. Broad Spectrum Antiviral Agent Niclosamide ' 'and Its Therapeutic Potential. ACS Infect Dis. 2020;6(5):909–15.', 'journal-title': 'ACS Infect Dis'}, { 'key': '3112_CR20', 'unstructured': 'Bayer. YOMESAN® tablets (MSDS) ' 'https://www.bayer.co.za/static/documents/MSDS/PIs/YOMESAN_EN_PI.pdf. ' '2008 Accessed on 2021–11–21.'}, { 'key': '3112_CR21', 'first-page': '6', 'volume': '37', 'author': 'GJ Abrams', 'year': '1963', 'unstructured': 'Abrams GJ, Seftel HC, Heinz HJ. The treatment of human tapeworm ' 'infections with ‘Yomesan.’ S Afr Med J. 1963;37:6–8.', 'journal-title': 'S Afr Med J'}, { 'key': '3112_CR22', 'doi-asserted-by': 'publisher', 'first-page': '89', 'DOI': '10.1016/j.cellsig.2017.04.001', 'volume': '41', 'author': 'W Chen', 'year': '2018', 'unstructured': 'Chen W, Mook RA, Premont RT, Wang J. Niclosamide: Beyond an ' 'antihelminthic drug. Cell Signal. 2018;41:89–96.', 'journal-title': 'Cell Signal'}, { 'key': '3112_CR23', 'unstructured': 'Goulding J. Virus Replication ' 'https://www.immunology.org/public-information/bitesized-immunology/pathogens-and-disease/virus-replication. ' 'British Society for Immunology 2021. Accessd on 2021–11–21.'}, { 'key': '3112_CR24', 'doi-asserted-by': 'crossref', 'unstructured': 'Laise P, Bosker G, Sun X, Shen Y, Douglass EF, Karan C, et al. The Host ' 'Cell ViroCheckpoint: Identification and Pharmacologic Targeting of Novel ' 'Mechanistic Determinants of Coronavirus-Mediated Hijacked Cell States. ' 'bioRxiv : the preprint server for biology. 2020:2020.05.12.091256.', 'DOI': '10.1101/2020.05.12.091256'}, { 'key': '3112_CR25', 'unstructured': 'Needham D. A White Paper. Why Niclosamide? A Basis for New Nasal and ' 'Throat Spray Solution-Formulation for COVID19 and Other Viral ' 'Infections. In preparation, to be submitted to Pharmaceutical Research. ' '2021.'}, { 'issue': '11', 'key': '3112_CR26', 'doi-asserted-by': 'publisher', 'first-page': '1435', 'DOI': '10.1164/rccm.202003-0572LE', 'volume': '201', 'author': 'Y Huang', 'year': '2020', 'unstructured': 'Huang Y, Chen S, Yang Z, Guan W, Liu D, Lin Z, et al. SARS-CoV-2 Viral ' 'Load in Clinical Samples from Critically Ill Patients. Am J Respir Crit ' 'Care Med. 2020;201(11):1435–8.', 'journal-title': 'Am J Respir Crit Care Med'}, { 'issue': '21', 'key': '3112_CR27', 'doi-asserted-by': 'publisher', 'first-page': '11727', 'DOI': '10.1073/pnas.2003138117', 'volume': '117', 'author': 'J Shang', 'year': '2020', 'unstructured': 'Shang J, Wan Y, Luo C, Ye G, Geng Q, Auerbach A, et al. Cell entry ' 'mechanisms of SARS-CoV-2. Proc Natl Acad Sci U S A. ' '2020;117(21):11727–34.', 'journal-title': 'Proc Natl Acad Sci U S A'}, { 'issue': '1', 'key': '3112_CR28', 'doi-asserted-by': 'publisher', 'first-page': '8682', 'DOI': '10.1038/s41598-019-45095-1', 'volume': '9', 'author': 'E Jung', 'year': '2019', 'unstructured': 'Jung E, Nam S, Oh H, Jun S, Ro H-J, Kim B, et al. Neutralization of ' 'Acidic Intracellular Vesicles by Niclosamide Inhibits Multiple Steps of ' 'the Dengue Virus Life Cycle In Vitro. Sci Rep. 2019;9(1):8682.', 'journal-title': 'Sci Rep'}, { 'issue': '6', 'key': '3112_CR29', 'doi-asserted-by': 'publisher', 'first-page': '2962', 'DOI': '10.1016/S0021-9258(18)69162-8', 'volume': '263', 'author': 'RC Conaway', 'year': '1988', 'unstructured': 'Conaway RC, Conaway JW. ATP activates transcription initiation from ' 'promoters by RNA polymerase II in a reversible step prior to RNA ' 'synthesis. J Biol Chem. 1988;263(6):2962–8.', 'journal-title': 'J Biol Chem'}, { 'key': '3112_CR30', 'doi-asserted-by': 'crossref', 'unstructured': 'Zimmerman JJ, von Saint André-von Arnim A, McLaughlin J. Chapter 74 - ' 'Cellular Respiration. In: Fuhrman BP, Zimmerman JJ, editors. Pediatric ' 'Critical Care (Fourth Edition). Saint Louis: Mosby; 2011. p. 1058–72.', 'DOI': '10.1016/B978-0-323-07307-3.10074-6'}, { 'key': '3112_CR31', 'unstructured': 'Promega. CellTiter-Glo® 2.0 Cell Viability Assay. ' 'https://www.promega.com/products/cell-health-assays/cell-viability-and-cytotoxicity-assays/celltiter_glo-2_0-assay. ' '2021 (Accessd on 2021–11–21).'}, { 'issue': '1', 'key': '3112_CR32', 'doi-asserted-by': 'publisher', 'first-page': '80-', 'DOI': '10.1186/1423-0127-16-80', 'volume': '16', 'author': 'C-W Chang', 'year': '2009', 'unstructured': 'Chang C-W, Li H-C, Hsu C-F, Chang C-Y, Lo S-Y. Increased ATP generation ' 'in the host cell is required for efficient vaccinia virus production. J ' 'Biomed Sci. 2009;16(1):80-.', 'journal-title': 'J Biomed Sci.'}, { 'key': '3112_CR33', 'doi-asserted-by': 'publisher', 'first-page': '56', 'DOI': '10.3390/v12010056', 'volume': '12', 'author': 'PD Nagy', 'year': '2020', 'unstructured': 'Nagy PD, Lin W. Taking over Cellular Energy-Metabolism for TBSV ' 'Replication: The High ATP Requirement of an RNA Virus within the Viral ' 'Replication Organelle. Viruses. 2020;12:56.', 'journal-title': 'Viruses'}, { 'key': '3112_CR34', 'unstructured': 'Kim S, Bear S, Needham D, Lee P. Effect of Niclosamide on cytotoxicity ' 'and cell viability in small airway epithelial cells in preparation. ' '2021.'}, { 'key': '3112_CR35', 'doi-asserted-by': 'crossref', 'unstructured': 'Ko M, Jeon S, Ryu W-S, Kim S. Comparative analysis of antiviral efficacy ' 'of FDA-approved drugs against SARS-CoV-2 in human lung cells: Nafamostat ' 'is the most potent antiviral drug candidate. bioRxiv. ' '2020:2020.05.12.090035.', 'DOI': '10.1101/2020.05.12.090035'}, { 'key': '3112_CR36', 'unstructured': 'clinicaltrials.gov. COVID19 Niclosamide ' 'https://clinicaltrials.gov/ct2/results?term=Niclosamide&cond=Covid19. ' '2021 Accessd on 2021-11-21.'}, { 'key': '3112_CR37', 'unstructured': 'Daewoong-Pharmaceutical. Daewoong Pharmaceutical Partners with Tufts ' 'Medical Center for Phase 2 Clinical Trial with Niclosamide. ' 'https://www.prnewswire.com/news-releases/daewoong-pharmaceutical-partners-with-tufts-medical-center-for-phase-2-clinical-trial-with-niclosamide-301162739.html. ' '2020 Accessed on 2021–11–21.'}, { 'key': '3112_CR38', 'unstructured': 'Union-Therapeutics. UNION’s nasal spray for COVID-19 enters a 1,500 ' 'high-risk patient study. 2021.'}, { 'issue': '3', 'key': '3112_CR39', 'doi-asserted-by': 'publisher', 'first-page': '179', 'DOI': '10.1111/bcpt.12342', 'volume': '116', 'author': 'M Boegh', 'year': '2015', 'unstructured': 'Boegh M, Nielsen HM. Mucus as a barrier to drug delivery – understanding ' 'and mimicking the barrier properties. Basic Clin Pharmacol Toxicol. ' '2015;116(3):179–86.', 'journal-title': 'Basic Clin Pharmacol Toxicol'}, { 'issue': '1', 'key': '3112_CR40', 'doi-asserted-by': 'publisher', 'first-page': '555', 'DOI': '10.1016/j.ijpharm.2017.09.018', 'volume': '532', 'author': 'J Leal', 'year': '2017', 'unstructured': 'Leal J, Smyth HDC, Ghosh D. Physicochemical properties of mucus and ' 'their impact on transmucosal drug delivery. Int J Pharm. ' '2017;532(1):555–72.', 'journal-title': 'Int J Pharm'}, { 'key': '3112_CR41', 'doi-asserted-by': 'publisher', 'first-page': '299', 'DOI': '10.25004/IJPSDR.2017.090603', 'volume': '9', 'author': 'AD Paul', 'year': '2017', 'unstructured': 'Paul AD, Samatha P, Manasa SL, Munemma R, Supriya D. Modeling the oral ' 'cavity with mucoadhesive drug delivery systems - a potential alternative ' 'to conventional therapy. Int J Pharm Sci Drug Res. 2017;9:299–307.', 'journal-title': 'Int J Pharm Sci Drug Res'}, { 'issue': '2', 'key': '3112_CR42', 'doi-asserted-by': 'publisher', 'first-page': '429', 'DOI': '10.1016/j.cell.2020.05.042', 'volume': '182', 'author': 'YJ Hou', 'year': '2020', 'unstructured': 'Hou YJ, Okuda K, Edwards CE, Martinez DR, Asakura T, Dinnon KH 3rd, et ' 'al. SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in ' 'the Respiratory Tract. Cell. 2020;182(2):429-46.e14.', 'journal-title': 'Cell'}, { 'issue': '2', 'key': '3112_CR43', 'doi-asserted-by': 'publisher', 'first-page': '139', 'DOI': '10.1016/S0378-5173(99)00442-1', 'volume': '198', 'author': 'N Washington', 'year': '2000', 'unstructured': 'Washington N, Steele RJ, Jackson SJ, Bush D, Mason J, Gill DA, et al. ' 'Determination of baseline human nasal pH and the effect of intranasally ' 'administered buffers. Int J Pharm. 2000;198(2):139–46.', 'journal-title': 'Int J Pharm'}, { 'key': '3112_CR44', 'unstructured': 'Shah BAK. FLONASE (fluticasone propionate) nasal spray. Prescribing ' 'information. In: DPARP, editor. 2019.'}, { 'issue': '12', 'key': '3112_CR45', 'doi-asserted-by': 'publisher', 'first-page': '1723', 'DOI': '10.2165/00003495-200868120-00009', 'volume': '68', 'author': 'CM Baldwin', 'year': '2008', 'unstructured': 'Baldwin CM, Scott LJ. Mometasone furoate: a review of its intranasal use ' 'in allergic rhinitis. Drugs. 2008;68(12):1723–39.', 'journal-title': 'Drugs'}, {'key': '3112_CR46', 'unstructured': 'Merck. Prescribing information Nasonex. 1997.'}, { 'issue': '1', 'key': '3112_CR47', 'doi-asserted-by': 'publisher', 'first-page': '5', 'DOI': '10.1016/S0169-409X(01)00172-7', 'volume': '51', 'author': 'N Jones', 'year': '2001', 'unstructured': 'Jones N. The nose and paranasal sinuses physiology and anatomy. Adv Drug ' 'Deliv Rev. 2001;51(1):5–19.', 'journal-title': 'Adv Drug Deliv Rev'}, { 'key': '3112_CR48', 'unstructured': 'Needham D, inventor; Duke University, assignee. Current Provisional ' 'Patent Portfolio USPO: a) DU7305PROV, US 63/111,184 “ANTI-VIRAL ' 'NICLOSAMIDE COMPOSITIONS AS VIROSTATIC THERAPEUTICS AND METHODS OF ' 'MAKING AND USING SAME” (filed 11/9/2020). b) DU7185PROV, US 63/049,160, ' '“NICLOSASPRAY” AND “NICLOSADROPS” FOR BUCCAL/THROAT, NASAL, AND EYE ' 'DROPS AND METHODS OF USING SAME” (filed 7/8/2020). c) DU7175PROV, US ' '63/049,153, “ANTIVIRAL NICLOSAMIDE COMPOSITIONS AS VIROSTATIC ' 'THERAPEUTICS AND METHODS OF MAKING AND USING SAME” (filed 7/8/2020). d) ' 'DU7109PROV, US 63/021,250, “COMPOSITIONS COMPRISING NICLOSAMIDE AND ' 'METHODS OF USING SAME AS PROPHYLAXIS AND TREATMENT OF VIRAL INFECTIONS” ' '(filed 5/7/2020). e) DU6187PROV, US 63/021,241, PRECIPITATION OF ' 'HYDROPHOBIC DRUGS AS NANOCRYSTALS FOR INJECTION TO A SUBJECT AND METHODS ' 'OF USING SAME (filed 5/72020). f) DU7099PROV, US 63/014,748, ' '“COMPOSITIONS COMPRISING NICLOSAMIDE AND METHODS OF MAKING AND USING ' 'SAME FOR THE PROPHYLAXIS AND TREATMENT OF VIRAL INFECTIONS” (filed ' '4/24/2020). g) DU7065PROV2, US 63/111,785, “COMPOSITIONS AND ' 'FORMULATIONS COMPRISING NICLOSAMIDE AND METHODS OF MAKING AND USING SAME ' 'FOR THE TREATMENT OF VIRAL INFECTIONS” (filed 4/17/2020). h) DU7065PROV, ' 'US 63/006,527, “NICLOSAMIDE COMPOSITIONS AND METHODS OF USING SAME FOR ' 'THE TREATMENT OF VIRAL INFECTIONS” (filed 4/7/2020). i) DU7308PROV, US ' '63/007,007, “ANTI-VIRAL NICLOSAMIDE COMPOSITIONS AS VIROSTATIC ' 'THERAPEUTICS AND METHODS OF MAKING AND USING SAME” (filed 3/26/2020). ' 'USA2020.'}, { 'issue': '7', 'key': '3112_CR49', 'doi-asserted-by': 'publisher', 'first-page': 'e00819', 'DOI': '10.1128/AAC.00819-20', 'volume': '64', 'author': 'S Jeon', 'year': '2020', 'unstructured': 'Jeon S, Ko M, Lee J, Choi I, Byun SY, Park S, et al. Identification of ' 'Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs. ' 'Antimicrob Agents Chemother. 2020;64(7):e00819-e820.', 'journal-title': 'Antimicrob Agents Chemother'}, { 'key': '3112_CR50', 'doi-asserted-by': 'crossref', 'unstructured': 'CDC. COVID-19 Vaccine Breakthrough Infections Reported to CDC — United ' 'States, January 1–April 30, 2021, ' 'https://www.cdc.gov/mmwr/volumes/70/wr/mm7021e3.htm. 2021 Accessed on ' '2021–11–21.', 'DOI': '10.15585/mmwr.mm7021e3'}, { 'key': '3112_CR51', 'unstructured': 'Delta Variant Key to Breakthrough Infections in Vaccinated Israelis ' '[press release]. Medscape2021.'}, { 'key': '3112_CR52', 'unstructured': 'Ourworldindata. Share of people vaccinated against COVID-19, Jul 23, ' '2021. 2021.'}, { 'key': '3112_CR53', 'unstructured': 'Hernandez J. Nearly 94,000 Kids Got COVID-19 Last Week. They Were 15% Of ' 'All New Cases (August 10 2021). NPR; 2021.'}, { 'issue': '9', 'key': '3112_CR54', 'doi-asserted-by': 'publisher', 'first-page': '836', 'DOI': '10.1080/1061186X.2016.1238092', 'volume': '24', 'author': 'D Needham', 'year': '2016', 'unstructured': 'Needham D, Arslanagic A, Glud K, Hervella P, Karimi L, Høeilund-Carlsen ' 'P-F, et al. Bottom up design of nanoparticles for anti-cancer ' 'diapeutics. J Drug Target. 2016;24(9):836–56.', 'journal-title': 'J Drug Target'}, { 'issue': '7', 'key': '3112_CR55', 'doi-asserted-by': 'publisher', 'first-page': '1448', 'DOI': '10.1158/1535-7163.MCT-19-0689', 'volume': '19', 'author': 'GB Reddy', 'year': '2020', 'unstructured': 'Reddy GB, Kerr DL, Spasojevic I, Tovmasyan A, Hsu D, Brigman BE, et al. ' 'Preclinical Testing of a Novel Niclosamide Stearate Prodrug Therapeutic ' '(NSPT) shows efficacy against Osteosarcoma. Mol Cancer Ther. ' '2020;19(7):1448.', 'journal-title': 'Mol Cancer Ther.'}, { 'key': '3112_CR56', 'unstructured': 'FAO. Food and Agriculture Organization of the United Nations (FAO) ' 'SPECIFICATIONS AND EVALUATIONS FOR AGRICULTURAL PESTICIDES NICLOSAMIDE ' '2’,5-dichloro-4’-nitrosalicylanilide 2004.'}, { 'issue': '18', 'key': '3112_CR57', 'doi-asserted-by': 'publisher', 'first-page': '9998', 'DOI': '10.1021/acs.est.6b02607', 'volume': '50', 'author': 'MB McConville', 'year': '2016', 'unstructured': 'McConville MB, Hubert TD, Remucal CK. Direct Photolysis Rates and ' 'Transformation Pathways of the Lampricides TFM and Niclosamide in ' 'Simulated Sunlight. Environ Sci Technol. 2016;50(18):9998–10006.', 'journal-title': 'Environ Sci Technol'}, { 'key': '3112_CR58', 'doi-asserted-by': 'publisher', 'first-page': '425', 'DOI': '10.1016/j.chemosphere.2018.03.021', 'volume': '201', 'author': 'TH Tran', 'year': '2018', 'unstructured': 'Tran TH, Labanowski J, Gallard H. Adsorption and transformation of the ' 'anthelmintic drug niclosamide by manganese oxide. Chemosphere. ' '2018;201:425–31.', 'journal-title': 'Chemosphere'}, { 'issue': '1', 'key': '3112_CR59', 'doi-asserted-by': 'publisher', 'first-page': '1', 'DOI': '10.1023/A:1007931314609', 'volume': '31', 'author': 'MR Caira', 'year': '1998', 'unstructured': 'Caira MR, Van Tonder EC, De Villiers MM, Lötter AP. Diverse Modes of ' 'Solvent Inclusion in Crystalline Pseudopolymorphs of the Anthelmintic ' 'Drug Niclosamide. J Inclusion Phenom Mol Recognit Chem. 1998;31(1):1–16.', 'journal-title': 'J Inclusion Phenom Mol Recognit Chem'}, { 'issue': '6', 'key': '3112_CR60', 'doi-asserted-by': 'publisher', 'first-page': '581', 'DOI': '10.1081/DDC-120037489', 'volume': '30', 'author': 'MM de Villiers', 'year': '2004', 'unstructured': 'de Villiers MM, Mahlatji MD, van Tonder EC, Malan SF, Lötter AP, ' 'Liebenberg W. Comparison of the physical and chemical stability of ' 'niclosamide crystal forms in aqueous versus nonaqueous suspensions. Drug ' 'Dev Ind Pharm. 2004;30(6):581–92.', 'journal-title': 'Drug Dev Ind Pharm'}, { 'issue': '1', 'key': '3112_CR61', 'doi-asserted-by': 'publisher', 'first-page': 'E12-E', 'DOI': '10.1007/BF02830580', 'volume': '5', 'author': 'EC van Tonder', 'year': '2004', 'unstructured': 'van Tonder EC, Mahlatji MD, Malan SF, Liebenberg W, Caira MR, Song M, et ' 'al. Preparation and physicochemical characterization of 5 niclosamide ' 'solvates and 1 hemisolvate. AAPS PharmSciTech. 2004;5(1):E12-E.', 'journal-title': 'AAPS PharmSciTech.'}, { 'key': '3112_CR62', 'unstructured': 'Burley J, Needham D. Characterization of Niclosamide (XRD, FT-IR/Raman, ' 'DSC) from various suppliers and as precipitates and cosolvates confirms ' 'polymorphic forms as a function of pH (in preparation). 2021.'}, { 'key': '3112_CR63', 'doi-asserted-by': 'publisher', 'first-page': '1092', 'DOI': '10.1119/1.2772287', 'volume': '75', 'author': 'G Halász', 'year': '2007', 'unstructured': 'Halász G, Gyüre B, Jánosi IM. Vortex flow generated by a magnetic ' 'stirrer. Am J Phys. 2007;75:1092.', 'journal-title': 'Am J Phys'}, { 'issue': '7', 'key': '3112_CR64', 'doi-asserted-by': 'publisher', 'first-page': '2567', 'DOI': '10.1021/la034930i', 'volume': '20', 'author': 'PB Duncan', 'year': '2004', 'unstructured': 'Duncan PB, Needham D. Test of the Epstein-Plesset model for gas ' 'microparticle dissolution in aqueous media: Effect of surface tension ' 'and gas undersaturation in solution. Langmuir. 2004;20(7):2567–78.', 'journal-title': 'Langmuir'}, { 'issue': '9', 'key': '3112_CR65', 'doi-asserted-by': 'publisher', 'first-page': '4190', 'DOI': '10.1021/la053314e', 'volume': '22', 'author': 'PB Duncan', 'year': '2006', 'unstructured': 'Duncan PB, Needham D. Microdroplet dissolution into a second-phase ' 'solvent using a micropipet technique: Test of the Epstein-Plesset model ' 'for an aniline-water system. Langmuir. 2006;22(9):4190–7.', 'journal-title': 'Langmuir'}, { 'issue': '11', 'key': '3112_CR66', 'doi-asserted-by': 'publisher', 'first-page': '1505', 'DOI': '10.1063/1.1747520', 'volume': '18', 'author': 'PS Epstein', 'year': '1950', 'unstructured': 'Epstein PS, Plesset MS. On the Stability of Gas Bubbles in Liquid-Gas ' 'Solutions. J Chem Phys. 1950;18(11):1505–2409.', 'journal-title': 'J Chem Phys'}, { 'issue': '44', 'key': '3112_CR67', 'doi-asserted-by': 'publisher', 'first-page': '13339', 'DOI': '10.1021/la402533j', 'volume': '29', 'author': 'JT Su', 'year': '2013', 'unstructured': 'Su JT, Needham D. Mass transfer in the dissolution of a multicomponent ' 'liquid droplet in an immiscible liquid environment. Langmuir. ' '2013;29(44):13339–45.', 'journal-title': 'Langmuir'}, { 'issue': '20', 'key': '3112_CR68', 'doi-asserted-by': 'publisher', 'first-page': '8455', 'DOI': '10.1021/la034779c', 'volume': '19', 'author': 'DH Kim', 'year': '2003', 'unstructured': 'Kim DH, Costello MJ, Duncan PB, Needham D. Mechanical properties and ' 'microstructure of polycrystalline phospholipid monolayer shells: Novel ' 'solid microparticles. Langmuir. 2003;19(20):8455–66.', 'journal-title': 'Langmuir'}, { 'issue': '2', 'key': '3112_CR69', 'first-page': 'A313-A', 'volume': '74', 'author': 'DH Kim', 'year': '1998', 'unstructured': 'Kim DH, Klibanov AL, Evans EA, Needham D. Viscoelastic properties of ' 'phospholipid monolayer shells on air microbubbles. Biophys J. ' '1998;74(2):A313-A.', 'journal-title': 'Biophys J.'}, { 'issue': '2', 'key': '3112_CR70', 'doi-asserted-by': 'publisher', 'first-page': '379', 'DOI': '10.1107/S0021889807007832', 'volume': '40', 'author': 'A Llinàs', 'year': '2007', 'unstructured': 'Llinàs A, Box KJ, Burley JC, Glen RC, Goodman JM. A new method for the ' 'reproducible generation of polymorphs: two forms of sulindac with very ' 'different solubilities. J Appl Crystallogr. 2007;40(2):379–81.', 'journal-title': 'J Appl Crystallogr'}, { 'key': '3112_CR71', 'doi-asserted-by': 'crossref', 'unstructured': 'Jara MO, Warnken ZN, Sahakijpijarn S, Moon C, Maier EY, Christensen DJ, ' 'et al. Niclosamide Inhalation Powder Made by Thin-Film Freezing: ' 'Pharmacokinetic and Toxicology Studies in Rats and Hamsters. bioRxiv. ' '2021:2021.01.26.428293.', 'DOI': '10.1101/2021.01.26.428293'}, { 'key': '3112_CR72', 'unstructured': 'Union-Therapeutics. UNION therapeutics A/S completes dosing of healthy ' 'volunteers with UNI911 (inhaled niclosamide) for COVID-19 ' 'https://www.uniontherapeutics.com/news-events/news/union-therapeutics-a-s-completes-dosing-of-healthy-volunteers-with-uni911-inhaled-niclosamide-for-covid-19. ' '2020 Accessed on 2021–11–21.'}, { 'key': '3112_CR73', 'unstructured': 'CDC. Global COVID-19 Vaccinations ' 'https://covid.cdc.gov/covid-data-tracker/#global-vaccinations. 2021 ' 'Accessed on 2021–11–21.'}], 'container-title': 'Pharmaceutical Research', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://link.springer.com/content/pdf/10.1007/s11095-021-03112-x.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/article/10.1007/s11095-021-03112-x/fulltext.html', 'content-type': 'text/html', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/content/pdf/10.1007/s11095-021-03112-x.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2022, 10, 28]], 'date-time': '2022-10-28T02:14:32Z', 'timestamp': 1666923272000}, 'score': 1, 'resource': {'primary': {'URL': 'https://link.springer.com/10.1007/s11095-021-03112-x'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2021, 12, 28]]}, 'references-count': 73, 'journal-issue': {'issue': '1', 'published-print': {'date-parts': [[2022, 1]]}}, 'alternative-id': ['3112'], 'URL': 'http://dx.doi.org/10.1007/s11095-021-03112-x', 'relation': { 'has-preprint': [ { 'id-type': 'doi', 'id': '10.1101/2021.08.16.456531', 'asserted-by': 'object'}]}, 'ISSN': ['0724-8741', '1573-904X'], 'subject': [ 'Pharmacology (medical)', 'Organic Chemistry', 'Pharmaceutical Science', 'Pharmacology', 'Molecular Medicine', 'Biotechnology'], 'container-title-short': 'Pharm Res', 'published': {'date-parts': [[2021, 12, 28]]}, 'assertion': [ { 'value': '13 August 2021', 'order': 1, 'name': 'received', 'label': 'Received', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '14 September 2021', 'order': 2, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '28 December 2021', 'order': 3, 'name': 'first_online', 'label': 'First Online', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, {'order': 1, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Declarations'}}, { 'value': 'Duke University has assigned the rights for the provisional patent applications ' 'to David Needham and his entity, Needham Material Science LLC.', 'order': 2, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Conflict of Interest Statement'}}, { 'value': 'David Needham was the sole contributor and sole author.', 'order': 3, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Author contributions for all authors'}}, { 'value': 'The datasets generated during and/or analyzed during the current study are ' 'available from the corresponding author on reasonable request.', 'order': 4, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Data Availability Statement'}}, { 'value': 'This content has been made available to all.', 'name': 'free', 'label': 'Free to read'}]}